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SUMMARY
Notch1 is a proto-oncogene in several organs. In the skin, however,Notch1deletion leads to tumor formation,
suggesting that Notch1 is a ‘‘tumor suppressor’’ within this context. Here we demonstrate that, unlike clas-
sical tumor suppressors, Notch1 loss in epidermal keratinocytes promotes tumorigenesis non-cell autono-
mously by impairing skin-barrier integrity and creating a wound-like microenvironment in the skin. Using
mice with a chimeric pattern of Notch1 deletion, we determined that Notch1-expressing keratinocytes in
this microenvironment readily formed papillomas, showing that Notch1 was insufficient to suppress this
tumor-promoting effect. Accordingly, loss of other Notch paralogues that impaired the skin barrier also pre-
disposed Notch1-expressing skin to tumorigenesis, demonstrating that the tumor-promoting effect of
Notch1 loss involves a crosstalk between barrier-defective epidermis and its stroma.INTRODUCTION
Notch proteins are transmembrane receptors activated upon
binding of transmembrane ligands and are implicated in many
developmental and cellular processes, including carcinogen-
esis. Notch activation involves two sequential proteolytic cleav-
ages releasing the Notch intracellular domain, a transcription
regulator, into the nucleus (Lubman et al., 2004). Based on its
role in most cancers involving Notch signaling (e.g., T-acute
lymphoblastic leukemia), Notch1 is a proto-oncogene, driving
carcinogenesis cell autonomously when hyperactivated or hy-
perstabilized (Radtke et al., 2006; Weng et al., 2004). In contrast,
an opposite role for Notch1 is observed in skin keratinocytes,
where it acts as a ‘‘tumor suppressor’’ (Koch and Radtke,
2007; Nicolas et al., 2003). The mechanism enabling Notch1 to
deliver this unique function in skin remains controversial.
The vertebrate skin is a barrier-forming organ in which kerati-
nocytes form a highly organized, stratified epithelium protecting
the internal milieu from the outside environment. To achieve this,
proliferating keratinocyte progenitors residing within the inner-most (basal) layer of the epidermis constantly divide and
replenish the upper barrier-forming layers (Clayton et al., 2007).
Cells exiting the basal layer gradually commit to terminal differ-
entiation in the spinous layer and, under normal conditions,
complete their differentiation program, giving rise to granular
and cornified layers (Fuchs and Raghavan, 2002; Jamora and
Fuchs, 2002). Three Notch paralogues (Notch1, -2, and -3) are
expressed in the epidermis and their activation is evident in
suprabasal keratinocytes. Importantly, reduction in Notch
signaling within keratinocytes impairs their ability to execute
the terminal differentiation program, resulting in formation of
a defective skin-barrier and death if the areas involved are suffi-
ciently large (Blanpain et al., 2006; Demehri et al., 2008).
One of the major adverse consequences of Notch loss in
epidermis is the development of skin tumors (Nicolas et al.,
2003; Proweller et al., 2006), evoking the use of the term ‘‘tumor
suppressor’’ to specifically describe the role of Notch1 in the
epidermis (Nicolas et al., 2003). However, the exact mechanism
underlying Notch1 tumor suppressor function, and why specific
consequences of Notch1 loss cannot be compensated for bySIGNIFICANCE
In contrast to the current dogma, we demonstrate unequivocally that the non-cell autonomous consequences of defective
barrier formation are responsible for the tumor-promoting effects of Notch1 loss in mouse skin. Thus, individuals with
subacute skin-barrier defects may also be prone to carcinogenesis upon exposure to initiating carcinogens like UV rays.
As Notch1 deletion in skin tumors enhanced their progression to invasive carcinomas, patients with benign hyperplasic
skin lesions receiving g-secretase inhibitor therapy may, therefore, be at additional risk. More broadly, given that chronic
injury causatively effects the development of several human carcinomas, Notch1-deficient mice with mild skin-barrier
defects can serve as an experimental model in which to study the tumor-promoting elements of chronic injury/wound
and develop relevant therapies.
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Notch1 Loss Creates a Tumor-Promoting EnvironmentFigure 1. Msx2-N1CKOMice Develop Skin Tumors
Spontaneously and in Response to Chemical
Carcinogens
(A) Spontaneous skin tumorigenesis of Msx2-N1CKO
mice and their wild-type littermates (n = 20 for each group;
p < 0.0001, log rank test).
(B) A representative Msx2-N1CKO mouse with two papil-
lomas (left) and one BCC (right) at P593. Scale bars,
500 mm.
(C) Schematic diagram outlining the standard DMBA/TPA
treatment protocol used for skin carcinogenesis studies.
Two days prior to treatment with DMBA (black arrow-
head), the back skin of the animals are shaved to ensure
the hair follicles are in telogen (rest) phase.
(D) DMBA/TPA-induced skin tumorigenesis of Msx2-
N1CKO and their wild-type littermates (n = 10 for each
group; p < 0.0001, log rank test).
(E) The average number of papillomas per each tumor-
bearing mutant mouse observed over a 25 week follow-
up period. Beginning at 20 weeks after initiation, >50%
of Msx2-N1CKO mice have more than 20 papillomas
(*p < 0.05, Student’s t test). These findings are confirmed
in additional independent experiments. All error bars
represent ± SD.other Notch paralogues present in the skin (i.e., Notch2 and -3),
are not fully understood. It has been proposed that the tumor
suppressor activity of Notch1 reflects its unique ability to antag-
onize keratinocyte proliferation through one or more cell auto-
nomous signaling mechanisms. Most of these findings were
established in precancerous hyperplastic epidermis of Notch-
deficient animals (Nicolas et al., 2003; Proweller et al., 2006)
and did not examine the early changes following Notch loss.
Other conclusions were based on in vitro studies with isolated
keratinocytes (Devgan et al., 2005; Nguyen et al., 2006; Nicolas
et al., 2003), failing to take into account the complexity of the skin
microenvironment, including the contribution of other skin com-
ponents to carcinogenesis. Notably, in vivo studies have re-
vealed that loss of Notch signaling during embryogenesis
induces epidermal hypoplasia and low proliferative capacity in
the keratinocytes, proposing that reactive, i.e., secondary,
hyperplasia accounts for the late epidermal hyperproliferation
detected in adult Notch-deficient skin (Blanpain et al., 2006; De-
mehri et al., 2008). This also implies that the molecular changes
outlined above may reflect secondary events following
epidermal hyperplasia in Notch-deficient mice.
In this study, we investigate the mechanism underlying tumor
development in Notch1-deficient skin in vivo using the multi-
stage skin chemical carcinogenesis model (Zoumpourlis et al.,
2003). In this well-established carcinogenesis model, treating
the skin with an initiating carcinogen, 7,12-dimethylbenz[a]
anthracene (DMBA), results in an activating mutation in the
H-ras gene and creation of ‘‘initiated cells.’’ Thereafter, the
continual exposure of the skin to a tumor-promoting agent, tet-
radecanoylphorbol acetate (TPA), leads to expansion of the initi-
ated cells and eventually to tumor development. In addition, we
took advantage of two Cre-expressing transgenes. K14CreERT
(Vasioukhin et al., 1999) allows us to generate mice in which
we can control the timing of epidermal Notch1 deletion relative
to DMBA treatment. Msx2-Cre is ectopically expressed at
embryonic day (E) 9.5 in clusters of ectodermal cells prior to56 Cancer Cell 16, 55–66, July 7, 2009 ª2009 Elsevier Inc.the onset of skin morphogenesis, but its expression is never
again detected in the epidermis after E13. This chimeric pattern
of Cre expression allows us to generate mice with a chimeric
pattern of Notch1 deletion in skin keratinocytes with three types
of epidermal territories: (1) clones of epidermal cells on dorsal
and ventral midline with complete deletion of Notch1-floxed
alleles showing alopecia; (2) territories with functional proteins
expressed from undeleted floxed alleles exhibiting normal
epidermal and hair growth; and (3) border regions between the
two in which cells of both genotypes mingle (Demehri et al.,
2008; Pan et al., 2004) (see Figure S1 available online). This
chimeric animal model permits a direct comparison of cells
with identical genetic backgrounds, other than the deleted
alleles, in the same microenvironment.
RESULTS
Animals with Chimeric Loss of Notch1
in the Epidermis Develop Skin Tumors
As reported in animals with 4-hydroxytamoxifen (4-OHT)-
induced deletion of Notch1 in the epidermis (Nicolas et al.,
2003), most 20-month-old Msx2-Cre; Notch1flox/flox (Msx2-
N1CKO) mice spontaneously developed one to four skin tumors
each (Figure 1A). These lesions were predominantly composed
of benign papillomas; however, 4 out of 41 spontaneous tumors
characterized progressed to basal cell carcinoma (BCC;
Figure 1B). To study the mechanism linking Notch1 loss to skin
carcinogenesis in an in vivo setting that permitted analysis of
mutant and wild-type cells in the same environment, we exam-
ined the response of Msx2-N1CKO animals to the multistage
chemical skin carcinogenesis model (Figure 1C). Treating 6- to
10-week-old Msx2-N1CKO and wild-type (Notch1flox/flox) litter-
mates with a single initiating dose of DMBA, followed by a twice
weekly dose of TPA for 14 weeks (Nicolas et al., 2003), resulted in
development of more than 20 papillomas/mouse in all DMBA/
TPA-treated Msx2-N1CKO animals, whereas none of the control
Cancer Cell
Notch1 Loss Creates a Tumor-Promoting Environmentanimals developed any papillomas after 25 weeks of follow-up
(Figures 1D–1E and Tables S1 and S2). These results reproduce
the tumor phenotype reported (Nicolas et al., 2003) and establish
thatNotch1 loss, even in a fraction of epidermal cells, is sufficient
to sensitize the animals to chemical carcinogenesis.
Notch1 Loss Primarily Acts as a Tumor Promoter
in the Epidermis
We next tested the impact of Notch1 loss on distinct stages of
skin tumor development (Zoumpourlis et al., 2003). The appear-
ance of spontaneous tumors on Msx2-N1CKO skin could reflect
a role for Notch1 in initiation, in which case tumors would be
expected to develop earlier in Msx2-N1CKO mice exposed to
TPA alone. However, 6- to 10-week-old Msx2-N1CKO animals
treated only with a high dose of TPA twice weekly for 25 weeks
developed hyperplasia but did not develop any tumors (n = 10;
Figure 2A), indicating that deletion of Notch1 did not act as
a tumor initiator nor did its loss lead to the activation of one.
Accordingly, we were unable to detect an elevated Gli2 expres-
sion or elevated Wnt/b-catenin signaling (seen at 6 weeks of age
or older) (Nicolas et al., 2003; Proweller et al., 2006) in 2-week-
old Notch-deficient skin (Figure S2). However, given that the
direct Notch1 targets in skin keratinocytes, Hes1 and Hey1,
are repressors of HDM2 (Huang et al., 2004), Notch1 loss might
have led to elevated MDM2 and destabilization of p53, thereby
Figure 2. Epidermal Deletion of Notch1 Leads
Primarily to Skin Tumor Promotion
(A) Treating Msx2-N1CKO and wild-type skin with TPA
(18 mg/mouse) twice weekly for 25 weeks (arrow) does
not result in tumor growth in the mutant mice. An example
of Msx2-N1CKO and wild-type skins with high doses of
TPA (18 mg per mouse; arrow) twice weekly for 25 weeks.
Scale bars, 100 mm.
(B) Schematic diagram detailing K14ERT-N1CKO treat-
ment protocol. Six- to ten-week-old K14ERT-N1CKO
mice are treated with 4-OHT for 5 days at the indicated
points (red arrowheads) to induce Notch1 deletion.
(C and D) Notch1 deletion was induced by 4-OHT injec-
tions beginning 4 days after DMBA-mediated tumor initia-
tion (DOT) induced skin carcinogenesis to a similar level as
did Notch1 deletion 9 days prior to DMBA treatment
(ODT). BothNotch1-deficient cohorts develop skin tumors
earlier (C) and in significantly higher numbers than controls
(p < 0.05 for all tumor counts after week 9, Student’s t test)
(D). The ODT group has significantly more tumors than the
DOT group at the last two time points (*p = 0.017; **p =
0.014, Student’s t test).
(E and F) Msx2-N1CKO mice treated topically with one
dose of DMBA (150 mg per mouse) develop skin tumors
in the absence of TPA (E) starting at 10 weeks after
DMBA treatment and gain a few papillomas per each
tumor-bearing mouse (F). No papilloma is formed in
DMBA-treated, wild-type littermates (n = 10 for each
group; p < 0.0001, log rank test). These data are confirmed
in additional independent experiments. All error bars
represent ± SD.
facilitating H-ras-mediated transformation of
DMBA-treated keratinocytes (Zhao et al.,
2006). In addition, Notch1 loss could contribute
to tumor initiation by lowering p21WAF1/Cip1
expression in keratinocytes (Nicolas et al., 2003; Rangarajan
et al., 2001). Therefore, we examined the possibility that Notch1
loss contributed to the fixation rate of DMBA-induced DNA
mutation in basal keratinocytes. We treated 6- to 10-week-old
K14CreERT; Notch1flox/flox (K14ERT-N1CKO) animals with 4-
OHT to remove Notch1 either before (OHT/ DMBA/ TPA, or
ODT) or after (DMBA/ OHT/ TPA, or DOT) DMBA exposure
(Figure 2B). As judged by time to tumor onset, both cohorts
displayed a similarly elevated susceptibility to carcinogenesis
over the 4-OHT-treated controls (K14CreERT; Notch1flox/+), indi-
cating that Notch1 loss did not contribute to a p21WAF1/Cip1- or
p53-controlled checkpoint (Figure 2C and Table S1). Although
the ODT cohort developed more tumors in the final 2 weeks of
the follow-up period, both cohorts had comparable tumor
counts during the first 23 weeks that were significantly higher
than the wild-type tumor count (Figure 2D and Table S1).
Although our animals were kept in an outbred background with
variable strain susceptibility, nested ANOVA analysis showed
that the differences reported in this study were solely conferred
by the presence or absence of Notch1 (Tables S3). Collectively,
these data suggest that the main consequence of Notch1 loss is
in tumor promotion. Indeed, 100% of Msx2-N1CKO mice treated
only once with DMBA (n = 10) developed tumors, whereas none
of the wild-type controls (Notch1flox/flox; n = 10) did (p < 0.0001;
Figures 2E and 2F and Tables S1 and S4).Cancer Cell 16, 55–66, July 7, 2009 ª2009 Elsevier Inc. 57
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Notch1 Loss Creates a Tumor-Promoting EnvironmentFigure 3. Notch1 Loss in the Epidermis
Causes Malignant Progression of Skin
Tumors
(A) Schematic diagram outlining the method used
to address the role of Notch1 in tumor progres-
sion. Notch1 deletion was induced after papilloma
formation in K14CreERT background.
(B) Treatment of mice with 4-OHT starting after the
last TPA application (arrow) does not impact the
total number of tumors formed in the Notch1-
deleted (DTO) or control animals (n = 8 for each
group).
(C) A significant fraction (50%) of tumors in DTO
cohort progress to SCC, distinguishable on H&E-
stained histological section. In contrast, papil-
lomas on Notch1-expressing control skin show
no sign of malignant progression. Note that global
loss of Notch1 results in hair loss phenotype and
that SCC cells in Notch1-deficient skin invade
through the subcutaneous muscle layer (insets).
Scale bars, 500 mm.
(D) Malignant skin cancer in DTO mice has meta-
static features shown by the presence of AE1+
epidermal keratinocytes in a draining lymph node
of a representative DTO animal. Scale bars, 50 mm.
(E) Due to their severe skin cancers, DTO mice
become moribund and demise prematurely (p <
0.0001, log rank test). All error bars represent ± SD.As expected (Nicolas et al., 2003), subsets of papillomas from
the ODT and DOT groups progressed to invasive squamous cell
carcinoma (SCC) (Figure S3). Therefore, we examined the
impact of Notch1 loss on malignant progression. Intraperitoneal
injection of 4-OHT into K14ERT-N1CKO and control mice after
completion of the DMBA/TPA protocol (DTO) did not alter tumor
numbers (Figures 3A and 3B). Interestingly, malignant conver-
sion of papillomas to metastatic SCC was seen only in DTO
animals (Figures 3C and 3D). On average, 50% of Notch1-defi-
cient tumors progressed to SCC, which metastasized and
necessitated euthanasia of the moribund mice (Figure 3E).
Together, these in vivo cancer studies indicate that the primary
role of Notch1 in suppressing skin tumors is in blocking tumor
promotion and progression; the latter could be associated with
reduction in p53 (Huang et al., 2004) or with elevated activity of
Wnt and HH signaling in hyperplastic, Notch1-deficient cells
(Nicolas et al., 2003).
Notch1-Deficient Epidermis Creates
a Microenvironment Promoting Carcinogenesis
The tumor-promoting effect of Notch1 deletion can be mediated
by cell autonomous changes in the initiated cells that acquired
H-ras mutations, by non-cell autonomous signals emanating
from the surrounding environment that is responding to signals
produced by Notch1-deficient keratinocytes (Lee et al., 2007),
or by a combination of both. To determine which of these possi-
bilities best describes the contribution of Notch1 loss to skin
tumorigenesis, we reanalyzed Msx2-N1CKO mice exposed to
DMBA/TPA (Figure 1) and performed an intracomparison of
adjacent wild-type and Notch1-deficient territories within each
animal after DMBA/TPA treatment (Figure 4A). If Notch1 acted
like a classical tumor suppressor, initiated cells expressing
Notch1 would not be able to form tumors. In contrast to this58 Cancer Cell 16, 55–66, July 7, 2009 ª2009 Elsevier Inc.prediction, DMBA/TPA-treated Msx2-N1CKO; Rosa26R mice
had a comparable number of Cre-negative (white) papillomas
adjacent to the Cre-positive (blue) territory (Figure 4B). This is
consistent with Notch1-expressing tumors developing in
Msx2-N1CKO; Rosa26R animals. To confirm that tumors can
arise from initiated cells that did not experience Notch1 deletion,
we performed direct amplification of the Notch1 locus in tumor
DNA randomly collected from DMBA/TPA-treated Msx2-
N1CKO animals to estimate how many cells underwent Notch1
deletion (Figure 4C and Figure S4). Notch1 deletion was unde-
tectable in 33 out of 91 benign exophytic papillomas analyzed
by PCR with conditions sufficient to detect deletion in 1% of
genome equivalents. Since a significant subset of papillomas
contained more than 99% of genome equivalents contributed
by wild-type cells, we concluded that these tumors arose from
initiated cells that did not experience Notch1 deletion. Because
none of the wild-type littermates used in this study (n = 10) devel-
oped any tumors, this finding demonstrates that loss of Notch1
provides a promoting, non-cell autonomous signal that can
support papilloma formation from nearby initiated cells indepen-
dent of their Notch1 status. Given the absence of SCC among
DMBA/TPA-treated Msx2-N1CKO animals and the global nature
of Cre activation in K14ERT-N1CKO mice (Vasioukhin et al.,
1999), we could not examine if tumor progression to SCC was
a strict cell autonomous consequence of Notch1 loss.
Epidermal Differentiation/Barrier Formation Defects
Can Explain Tumor Promotion upon Notch1 Loss
Loss of Notch signaling in the skin causes impaired epidermal
differentiation, which in turn results in defective skin-barrier
formation (Figure S5) (Blanpain et al., 2006; Demehri et al.,
2008). After birth, the reactive epidermal hyperplasia masks
the physical consequences of skin-barrier impairments (i.e.,
Cancer Cell
Notch1 Loss Creates a Tumor-Promoting EnvironmentFigure 4. Notch1 Deletion in Epidermal Keratinocytes Acts as a
Non-Cell Autonomous Tumor Promoter
(A) The chimeric pattern of Notch1 deletion in Msx2-N1CKO animals enables
us to determine if the tumor-promoting effect of Notch1 loss in the skin is
the consequence of cell autonomous or non-cell autonomous changes.
Notch1-expressing skin patches (white) in Msx2-N1CKO animals serve as
an internal control to determine if Notch1-expressing initiated cells can form
skin tumors in an environment modified by neighboring, Notch1-deficient
cells. Considering that in this genetic background none of the DMBA/TPA-
treated wild-type littermates developed tumors (Figure 1), tumor growth in
white territory of Msx2-N1CKO skin would point to a non-cell autonomous
tumor-promoting signal from the environment conditioned by Notch1-deleted
(blue) cells.
(B) X-gal staining of representative Msx2-N1CKO;Rosa26R mouse treated
with DMBA/TPA shows the presence of a significant number of completely
white tumors (arrows) adjacent to Notch1-deleted (blue) skin territory. Note
the comparable size and number of white and blue tumors, consistent with
a dominant non-cell autonomous effect downstream of Notch1 loss that
results in tumor promotion in wild-type cells.dye penetration or transepidermal water loss) to ensure survival
in terrestrial life (Kuramoto et al., 2002). Nonetheless, thymic
stromal lymphopoietin (TSLP) and antimicrobial peptide overex-
pression can serve as reliable biomarkers for postnatal barrier
impairments (Aberg et al., 2008; Demehri et al., 2008; Kuramoto
et al., 2002). Based on these criteria, a mild barrier defect is also
detectable inMsx2-N1CKOskinatpostnatalday (P) 9 (FigureS6A)
(Demehri et al., 2008). The persistence of this barrier defect was
confirmed by documenting the overexpression of antimicrobial
peptides mRNA in the epidermis (Figure S6B) and upregulation
of serum TSLP levels in adult Msx2-N1CKO mice (Figure S7).
Notch pathway-deficient skin present initially with an
epidermal hypoplasia that resembles a chronic wound, thus
recruiting an array of cellular responders to repair the site of the
breach and resulting in the development of a reactive epidermal
hyperplasia over time (Blanpain et al., 2006; Segre, 2006).
Accordingly, Msx2-N1CKO epidermis was mildly hypoplastic at
birth, but exhibited a significant stromal hyperplasia as early as
P9 (Figure 5A). Following the proliferative changes in the dermis,
significant epidermal hyperplasia developed in adult mutants
(Figure 5A and Figure S8; Lee et al., 2007). Importantly, epidermal
hyperplasia extended beyondNotch1-deleted territories and into
adjacentNotch1-expressing epidermal regions (Figure 5B), indic-
ative of a non-cell autonomous proliferative mechanism.
The major stromal responses to a breach in the skin barrier
include infiltration of immune cells, activation of fibroblasts,
and angiogenesis, all of which provide proliferative signals to
keratinocytes as part of an integrated wound healing/barrier
repair response (Segre, 2006; Werner et al., 2007). To determine
the contribution of immune cells to reactive epidermal hyper-
plasia and tumor promotion in Msx2-N1CKO skin (Proweller
et al., 2006), we examined the number and composition of
dermal leukocytes in Msx2-N1CKO skin. An increase in CD45+
leukocytes was evident in Msx2-N1CKO skin by P9 (Figure 5C),
which was due predominantly to accumulation of CD4+ T cells in
the dermis of Msx2-N1CKO mice (Figure 5D and Figure S9).
Prominent increase in number of CD4+ T cells in dermis and
peripheral blood of adult Msx2-N1CKO mice together with
serum IgE elevation (Figure S10) is reminiscent of a mild atopic
dermatitis (AD)-like allergic inflammation, which represents a
typical immune response to skin-barrier defects (Segre, 2006).
In addition, dermal mast cells, another component of AD-like
inflammation (Navi et al., 2007), were significantly increased in
Msx2-N1CKO skin (Figure S11). Mast cell activation can
enhance skin carcinogenesis (de Visser et al., 2005). To examine
if this was critical for tumor promotion, we impaired mast cells
and neutrophils function by generating Msx2-N1CKO mice defi-
cient for cathepsin C (dipeptidyl peptidase I [DPPI] [Pham,
2006]). DMBA/TPA treatment of Msx2-Cre; Notch1flox/flox;
DPPI/ (Msx2-N1CKO;DPPI/), Msx2-N1CKO, DPPI+/, and
wild-type littermates demonstrated that mast cells did not play
a dominant role in tumor promotion since the inhibition of mast
(C) PCR analysis of DNA isolated from eight randomly selected Msx2-N1CKO
tumors from one individual confirms that Notch1 locus is intact (i.e., Notch1 is
not deleted) in >99% of tumor-forming cells in a substantial number of tumors
(D, deleted allele; M, molecular marker), demonstrating that these tumors have
arisen from Notch1-expressing initiated cells (see Figure S4 for the sensitivity
of the method).Cancer Cell 16, 55–66, July 7, 2009 ª2009 Elsevier Inc. 59
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Notch1 Loss Creates a Tumor-Promoting EnvironmentFigure 5. Notch1-Deficient Epidermis
Creates a Wound-like Microenvironment in
the Skin
(A) H&E staining of Msx2-N1CKO and wild-type
skin at birth (P0), P9, and 1 year of age demon-
strates the progression from relatively hypoplastic
epidermis in newborn Msx2-N1CKO animals to
distinct epidermal hyperplasia at 1 year. The
dermal hyperplasia, however, is evident as early
as P9. The bars on the left side of each picture
show the average thickness of epidermis (black)
and dermis (green) across three 1003microscope
fields. Scale bars, 50 mm.
(B) X-gal staining of 1-year-old Msx2-N1CKO skin
shows similar degree of hyperplasia (brackets) in
Notch1-expressing epidermis (red) and in the
Notch1-deleted territory (blue), consistent with
the presence of a dominant proliferative microen-
vironment in Msx2-N1CKO skin. Immunohisto-
chemical staining for the V1744 epitope (detecting
activated Notch1) confirms the presence of
Notch1 activity in hyperplastic epidermis adjacent
to the Notch1-deficient epidermis. Scale bars,
50 mm.
(C) Leukocyte infiltration into the dermis of Msx2-
N1CKO is detectable as early as P9 using CD45
pan-leukocyte marker (average number of CD45+
leukocytes in six randomly selected 2003 micro-
scope fields is tabulated). Scale bars, 50 mm.
(D) FC and cell counting methods are used
(Figure S9) to calculate the fold increase of dermal
immune cells in 6- to 8-month-old Msx2-N1CKO
animals relative to their wild-type controls (*p <
0.0001, Student’s t test).
(E and F) Treating Msx2-N1CKO;DPPI/ (n = 13),
Msx2-N1CKO (n = 14), DPPI/ (n = 12), and wild-
type (Notch1flox/flox; DPPI+/; n = 12) littermates
with DMBA/TPA excludes a dominant tumor-
promoting role for mast cells in Notch1-deficient
skin. Notch1-deficient mice are significantly
more prone to DMBA/TPA-induced tumor growth
than their Notch1-expressing counterparts (p <
0.0001, log rank test), and no major difference
was detected between Msx2-N1CKO;DPPI/
and Msx2-N1CKO animals with regard to time to
tumor onset (E) (p = 0.31, log rank test) or average
number of tumors per each tumor-bearing mouse
(F) (p = 0.12 at week 25 after initiation, Student’s
t test).
(G) Double staining of skin with a-SMA and an
endothelial marker (MECA-32) demonstrates the
abundance of myofibroblasts in adult Notch1-deficient skin (asterisk). Note the expansion of microvasculature in Notch1-deficient skin as early as P9 (arrows).
The arrowheads point to a-SMA-expressing arrector pili muscles. Scale bars, 50 mm.
(H) The number of dermal fibroblasts is significantly increased inNotch1-deficient skin. Dermal fibroblasts are counted in six random 2003microscope fields, and
the average ratio of Msx2-N1CKO to wild-type fibroblast counts at P9 and 1 year of age is presented (*p < 0.001 compared to wild-type, Student’s t test).
(I) Dermal fibroblasts in Notch1-deficient skin overexpress two major keratinocyte proliferative signals, SDF-1 and KGF, which are detected by qRT-PCR on total
skin mRNA samples (but not in epidermal mRNA [data not shown]) from P9 Msx2-N1CKO and wild-type mice (*p < 0.001 compared to wild-type, Student’s t test).
(J) Dermal view of dorsal skin shows expanded vascular network in 1-year-old Msx2-N1CKO skin compared to a wild-type littermate. Scale bars, 1 cm. All error
bars represent ± SD.cell/neutrophil function did not completely ameliorate the tumor-
promoting effect of the stroma in Notch1-deficient background
(Figures 5E and 5F). When nested ANOVA was applied to
account for the contribution of gender-based differences, a trend
toward delayed tumor onset and a significant reduction in tumor
counts at 20 weeks after DMBA treatment were detected in
Msx2-N1CKO;DPPI/ relative to Msx2-N1CKO mice (Table60 Cancer Cell 16, 55–66, July 7, 2009 ª2009 Elsevier Inc.S5). Thus, mast cells contribute to tumor promotion, but loss
of this contribution can be largely overcome by other tumor-
promoting factors.
Msx2-N1CKO epidermis overproduces TGF-b1 and TGF-b2
(Lee et al., 2007), the major diffusible keratinocyte factors that
recruit Gr-1+CD11b+ myeloid suppressor cells (Yang et al.,
2008) and activate dermal fibroblasts (Werner et al., 2007).
Cancer Cell
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carcinogenesis by suppressing immunosurveillance apparatus,
including cytotoxic CD8+ T cells (Bronte et al., 2000), were
increased in spleen of adult Msx2-N1CKO mice (Figure S12).
Activated fibroblasts, known to play an important role in tumor
promotion (Orimo and Weinberg, 2006), could also secrete
matrix-modifying proteins and mitogens leading to epidermal
hyperproliferation, establishing a ‘‘vicious cycle’’ (Lee et al.,
2007). In agreement with a vicious cycle involving TGF-b
signaling (Werner et al., 2007), Msx2-N1CKO dermal fibroblasts
were increased relative to wild-type at P9 and 1 year of age,
acquiring a myofibroblast phenotype as indicated by the expres-
sion of a-smooth muscle actin (a-SMA) in dermis of adult
Notch1-deficient mice (Figures 5G and 5H and Figure S13).
Accordingly, the expression levels of two fibroblast-derived
epidermal mitogens, keratinocyte growth factor (KGF or FGF-7)
and stromal cell-derived factor 1 (SDF-1 or CXCL-12) (Szabow-
ski et al., 2000; Werner et al., 2007), were modestly but signifi-
cantly upregulated in Notch1-deficient skin at P9 (1.6-fold, p <
0.001; Figure 5I). SDF-1 mRNA remained elevated in 6- to
8-month-old Msx2-N1CKO skin relative to wild-type littermates,
confirming the persistent overexpression of this factor over time
(Figure S14). Of note, the dermal vasculature also showed
increased branching and dilation in P9 and adult Msx2-N1CKO
skin, underscoring the gestalt of non-cell autonomous events
contributing to the tumor phenotype (Figures 5G and 5J). Taken
together, the consequences of persistent skin-barrier defects
in Msx2-N1CKO mice create a wound-like, proliferative microen-
vironment capable of driving epidermal hyperplasia and carcino-
genesis over time (Alberts et al., 2002; Eming et al., 2007; Parkin-
son, 1985).
All Notch Paralogues Involved in Barrier Formation
also Participate in Suppressing Skin Carcinogenesis
Loss of eitherNotch2 (Msx2-Cre; Notch2flox/flox or Msx2-N2CKO)
or Notch3 (Notch3/ or N3KO) in the skin had no phenotypic
consequences and, accordingly, no spontaneous epidermal
tumors appeared over the entire life span of these animals (n >
10 for each genotype; Figure S15A). Furthermore, the response
of Notch2- or Notch3-deficient mice to DMBA/TPA carcinogens
was indistinguishable from the wild-type littermates, reflecting
their respective strain’s baseline susceptibility (Figures S15B
and S15C). This result could reflect a unique contribution of
Notch1 to tumor suppression, perhaps by maintaining
p21WAF1/Cip1 expression (Devgan et al., 2005; Nguyen et al.,
2006; Nicolas et al., 2003; Okuyama et al., 2004). Alternatively,
if tumor promotion is mainly a consequence of an impaired
epidermal differentiation/barrier formation (the ‘‘defective
barrier’’ hypothesis), the lack of tumor susceptibility upon the
deletion of Notch2 or Notch3 could be because their loss, unlike
Notch1, did not compromise the skin barrier.
To differentiate between these possibilities, we first assessed
the contribution of Notch2 and Notch3 to the Notch1 ‘‘tumor
suppressor’’ function by analyzing an allelic series in which
Notch2 and Notch3 alleles were progressively removed on the
Msx2-N1CKO background. Removal of Notch2 and Notch3 in
Notch1-deficient skin exacerbates the barrier defects (Demehri
et al., 2008). In agreement with the defective barrier hypothesis,
this stepwise removal of Notch2 and Notch3 alleles in Msx2-N1CKO animals resulted in progressive enhancement of
epidermal hyperplasia at P9 (Figures 6A and 6B). We also
noticed a tight correlation between time to spontaneous tumor
onset and global Notch dose in keratinocytes (Figure 6C). This
demonstrates the existence of an additive function for Notch
paralogues in suppressing skin tumors as long as the overall
Notch dosage is reduced below a threshold; however, it does
not determine whether Notch1 makes a unique contribution to
tumor suppression in addition to its shared effect on proper
skin-barrier formation.
To examine if Notch1 has any unique tumor-suppressing
activity sufficient to prevent tumor formation in barrier-impaired
skin, we generated animals lacking Notch2 and Notch3 while re-
taining the expression of Notch1 (Msx2-Cre; Notch2flox/flox;
Notch3/ or Msx2-N2N3CKO). P9 Msx2-N2N3CKO epidermis
overexpressed TSLP and antimicrobial peptides, demonstrating
that keratinocytes lacking Notch2 and Notch3 formed a defective
skin barrier (Figures 7A and Figure S6). TSLP overexpression per-
sisted in adult Msx2-N2N3CKO mice and was accompanied by
serum IgE elevation that signified the development of a subacute
AD-like inflammation in response to persistent barrier defects in
these animals, similar to Msx2-N1CKO mice (Figures 7B and
7C and Figures S6 and S10B). Importantly, Msx2-N2N3CKO
epidermis retained normal expression ofp21wAF1/Cip1, confirming
the context-specific role of Notch1 in regulating p21wAF1/Cip1
expression (Figure 7A) (Nicolas et al., 2003). Nonetheless, dele-
tion of Notch2 in the skin of Notch3 null animals resulted in skin
hyperplasia (Figure 7D) and spontaneous tumors in the skin of
adult Notch1-expressing Msx2-N2N3CKO animals (Figures 7E
and 7F). As predicted from the defective barrier hypothesis,
exposure of Msx2-N2N3CKO mice to DMBA/TPA resulted in
a significantly higher tumor burden than that seen in control
littermates (Figures 7G and 7H), with many tumors progressing
to SCC (Figure 7I). Thus, blocking tumor progression is a
p21wAF1/Cip1-independent, shared function of the three Notch
receptors. Taken together, these findings indicate that the pres-
ence of Notch1 and p21wAF1/Cip1 is not sufficient to protect
barrier-defective skin from chemical carcinogens and instead
demonstrates that the tumor phenotype mirrors the progressive
defects in barrier formation and keratinocyte differentiation.
DISCUSSION
The fundamental observation that Notch1 deletion in epidermal
keratinocytes causes skin carcinogenesis is a clear deviation
from Notch1’s role as a proto-oncogene in several other organs
(Koch and Radtke, 2007). We examined the mechanism under-
lying the tumor-prone behavior of Notch1-deficient skin in mice
with a global or chimeric deletion pattern in their epidermis. We
established that Notch1 resembled most tumor suppressors in
that its loss was not involved in the initiating event of multistage
skin carcinogenesis (Zoumpourlis et al., 2003) by deleting
Notch1 either before or after DMBA treatment in the K14CreERT
system. However, Notch1 loss could effectively substitute for
TPA in the chemical carcinogenesis paradigm, establishing
unequivocally that its loss acts as a tumor-promoting event.
Delaying Notch1 deletion in K14CreERT mice until after the
tumor-promotion stage of carcinogenesis demonstrated that
late deletion of Notch1 contributed to malignant progression ofCancer Cell 16, 55–66, July 7, 2009 ª2009 Elsevier Inc. 61
Cancer Cell
Notch1 Loss Creates a Tumor-Promoting EnvironmentFigure 6. Stepwise Removal of Notch Paralogues in Msx2-N1CKO
Animals Leads to Progressively Worse Epidermal Hyperplasia that
Accelerates the Onset of Spontaneous Skin Carcinogenesis
(A) Skin histology of compound Notch-deficient mice at P9 demonstrates
progressive epidermal hyperplasia, hyperkeratosis, and dermal hyperplasia
as more Notch alleles are deleted. Note the disorganized epidermal cells
with atypia in Notch pathway-deficient skin (i.e., Msx2-N1N2N3CKO and
Msx2-PSDCKO). Scale bars, 50 mm.
(B) Although Msx2-N1CKO epidermis appears relatively normal at P9, Msx2-
PSDCKO skin that lacks all Notch signaling shows severely hyperplastic
epidermis, which overexpresses keratin 14 in suprabasal keratinocytes
(marking epidermal hyperplasia) and expresses keratin 6 (marking epidermal
dysplasia). Note that Msx2-PSDCKO skin is severely hypoplastic at birth
(Figure S5) (Demehri et al., 2008); Msx2-PSDCKO skin has thus undergone
an acute reactive hyperplasia in 9 days to repair its severe skin-barrier defect.
Scale bars, 50 mm.
(C) Progressive reduction in Notch signal dosage reduces the life span (De-
mehri et al., 2008) and time to spontaneous tumor onset. Lifelong monitoring
of 10 to 20 mice for each genotype reveals that severity of skin pathology
(shown in A) correlates inversely with lifespan, time to tumor onset, and tumor
penetrance (i.e., the percentage of animals with a given genotype that devel-
oped tumors) in compound Notch-deficient mice. Significant differences in62 Cancer Cell 16, 55–66, July 7, 2009 ª2009 Elsevier Inc.benign papillomas, a phenotype that is observed upon loss of
p53 but not loss of p21WAF1/Cip1 (Weinberg et al., 1999), a specific
Notch1 target in the skin (Rangarajan et al., 2001). Taken
together, we have conclusively determined that the main effect
of Notch1 loss is to provide the initiated cells with a proliferative
signal to form tumors and proceed to invasive carcinoma.
The proliferative signal that lies downstream of Notch1 loss
could be originated from within the initiated cells, substantiating
Notch1’s role as a classical tumor suppressor in skin keratino-
cytes (Nicolas et al., 2003). Alternatively, this signal could be
delivered by the skin microenvironment reacting to Notch1 loss
in the epidermis (Lee et al., 2007; Orimo and Weinberg, 2006;
Vauclair et al., 2007; Watt et al., 2008). The system we studied
allowed us to distinguish between these two possibilities; the
chimeric pattern of Notch1 deletion by Msx2-Cre created neigh-
boring territories of Notch1-expressing and Notch1-deficient
keratinocytes coexisting in the same microenvironment. Exam-
ining a large number of tumors isolated from DMBA/TPA-treated
Msx2-N1CKO mice clearly demonstrated that tumors comprised
mostly (>99%) of Notch1-expressing cells were as likely to form
as tumors comprised predominantly of Notch1-deleted cells in
the same environment. Thus, Notch1 loss in the epidermis
generates a non-cell autonomous signal, promoting tumorigen-
esis from any initiated cell exposed to the microenvironment
conditioned by Notch1-deficient keratinocytes. This finding
emphasizes the importance of the environment as an active
contributor to tumor development (Bissell and Radisky, 2001)
by showing that it can be the primary source of proliferative
signals to initiated cells.
To determine the identity of the tumor-promoting microenvi-
ronment formed as a consequence of Notch1 deletion in kerati-
nocytes, we reexamined the earliest effects ofNotch1 loss on the
skin. As previously shown, loss of Notch signaling leads to
impaired keratinocyte proliferation/differentiation culminating in
epidermal cell loss and defective skin-barrier function at birth
(Blanpain et al., 2006; Demehri et al., 2008; Rangarajan et al.,
2001). Therefore, we examined the hypothesis that Notch1-defi-
cient skin encompassed a chronic wound-like microenvironment
developing in response to barrier defects, which were the direct
consequence of Notch1 deletion in the epidermis (Blanpain
et al., 2006; Demehri et al., 2008). Indeed, the dermis of
Notch1-deficient skin contained the critical components of an
activated stroma responding to the breach in the skin barrier
including inflammatory cell infiltrate, activated fibroblasts, and
expanded vasculature (Mueller and Fusenig, 2004). To further
average time to tumor onset between adjacent genotypes are marked by
brackets. Although the shorting in life span for most genotypes is due directly
to their intrinsic skin phenotype including exfoliation, bleeding, and infection,
Msx2-N1N2CKO, Msx2-N1N2N3CKO, and Msx2-PSDCKO animals die
shortly after birth due to a lethal blood disorder (Demehri et al., 2008). Note
that Msx2-N2CKO and Notch3/ (N3KO) mice have normal skin and behave
like wild-type. Abbreviations used are as follows: Msx2-Cre/+; Notch1flox/flox
(Msx2-N1CKO),Msx2-Cre/+;Notch1flox/flox; Notch2flox/+ (Msx2-N1N2hCKO),Msx2-
Cre/+; Notch1flox/flox; Notch2flox/+; Notch3+/ (Msx2-N1N2hN3hCKO),
Msx2-Cre/+; Notch1flox/flox; Notch2flox/+; Notch3/ (Msx2-N1N2hN3CKO),
Msx2-Cre/+; Notch1flox/flox; Notch2flox/flox (Msx2-N1N2CKO), Msx2-Cre/+;
Notch1flox/flox; Notch2flox/flox; Notch3/ (Msx2-N1N2N3CKO), Msx2-Cre/+;
RBP-jflox/flox (Msx2-RBP-jCKO), and Msx2-Cre/+; PS1flox/flox; PS2/ (Msx2-
PSDCKO). All error bars represent ± SD.
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in the Skin Develop Skin-Barrier Defect,
Epidermal Hyperplasia, and Skin Tumors
(A) TSLP overexpression (a biomarker for post-
natal skin-barrier defects [Demehri et al., 2008])
is seen in both Notch1-deficient and Notch2/3-
deficient epidermis. mRNA for qRT-PCR analysis
is isolated from epidermis of P9 Msx2-N1CKO,
Msx2-N2N3CKO, and their wild-type littermates.
p21wAF1/Cip1 expression (a direct target of Notch1),
which is reduced in Notch1-deficient epidermis
and thought to be essential for tumor formation
in Notch1-deficient skin (Nicolas et al., 2003), is
not altered in Msx2-N2N3CKO epidermis.
However, TSLP mRNA level is highly elevated in
both Msx2-N1CKO and Msx2-N2N3CKO relative
to their wild-type controls (*p < 0.001; **p <
0.0001, Student’s t test).
(B) Serum TSLP levels remain elevated in adult
(6 to 8 months old) Msx2-N2N3CKO animals
implying the persistence of defective skin-barrier
in these mice (*p < 0.01, Student’s t test).
(C) The presence of a mild allergic inflammation
responding to skin-barrier defects in adult Msx2-
N2N3CKO mice is evident based on their elevated
serum IgE levels (n = 4 for each group; *p < 0.01,
Student’s t test).
(D) H&E staining of Msx2-Cre; Notch2flox/flox;
Notch3/ (Msx2-N2N3CKO) and wild-type skin
at P0, P9, and 1 year of age shows a Msx2-
N1CKO-like pattern of dermal hyperproliferation
starting at P9 and subsequent epidermal hyper-
plasia in 1-year-old mutant skin. The bars on the
left side of each picture show the average thick-
ness of epidermis (black) and dermis (green) across three 1003 microscope fields. Keratin 6 (K6) and keratin 14 (K14) immunofluorescence staining shows
distinct epidermal hyperplasia with dysplastic changes in 1-year-old Msx2-N2N3CKO skin. Scale bars, 50 mm.
(E) While none of Notch2flox/flox; Notch3/ (N3KO) or wild-type controls develop any skin tumor, Msx2-N2N3CKO mice develop spontaneous skin tumors over
time (n = 4; p < 0.0001, log rank test).
(F) A representative Msx2-N2N3CKO mouse (P418) is shown to demonstrate that the spontaneous tumors in Msx2-N2N3CKO skin are benign papillomas;
H&E-stained Msx2-N2N3CKO papilloma is also examined using K6 and K14 immunostaining (bottom). Scale bar, 200 mm.
(G) Treating Msx2-N2N3CKO and N3KO littermates with DMBA/TPA results in tumor formation in all Msx2-N2N3CKO mice (n = 14). In contrast, only 3 out
16 DMBA/TPA-treated N3KO animals develop tumors (p < 0.0001, log rank test).
(H) The average number of tumors per each tumor-bearing Msx2-N2N3CKO mouse is significantly higher than that among N3KO controls over the 25 week exper-
imental period (p < 0.05 for all tumor counts after week 8, Student’s t test).
(I) Analysis of all tumors present at week 25 after initiation show that N3KO control mice have only developed papillomas. In contrast, the majority of skin tumors in
DMBA/TPA-treated Msx2-N2N3CKO skin progress to SCC as confirmed by histological examination. All error bars represent ± SD.demonstrate that tumor promotion was the consequence of an
activated stroma responding to a general breach in the skin
barrier, we showed that mice lacking Notch2 and Notch3 in their
epidermis also developed skin tumors. This is in contrast to a
mechanistic model proposing that cell autonomous oncogenic
changes, specific to Notch1 loss (Rangarajan et al., 2001), are
the initial events mediating tumorigenesis in Notch1-deficient
skin. We find that the tumors in Notch1-deficient skin are the
end product of a complex interaction between a barrier-defec-
tive epidermis and its underlying stroma, which creates
a tumor-promoting feed-forward loop. This Notch1-indepen-
dent, barrier-dependent phenotype distinguishes Notch1 from
classical tumor suppressors. Accordingly, we predict that any
mouse model with mild chronic skin-barrier defects will also be
prone to skin tumorigenesis.
Fibroplasia, angiogenesis, and inflammation are stromal
elements intimately linked to wound repair (Martin, 1997). These
cellular changes are also closely associated with neoplastic trans-formation (Bissell and Radisky, 2001; Mueller and Fusenig, 2004).
It is proposed that the microenvironment of the non-healing
wound/defective skin barrier could be a risk factor for carcinogen-
esis (Eming et al., 2007). This association is supported by chem-
ical carcinogenesis studies showing that tumors grow at the
edges of skin wounds (Parkinson, 1985). In addition, it is sug-
gested that chronic injury can predispose various organs to
cancer (Bissell and Radisky, 2001) and there is clinical evidence
linking chronic skin wounds to BCC and SCC (Nguyen and Ho,
2002). For instance, leg ulcers significantly increase the risk of
SCC in patients (Baldursson et al., 1995). Nonetheless, experi-
mental evidence establishing that stromal changes in chronic
wound microenvironment can drive skin carcinogenesis is lack-
ing (Eming et al., 2007). Therefore, Msx2-N1CKO and Msx2-
N2N3CKO skin present a model demonstrating that a lengthened
stromal attempt to repair a non-healing wound or a persistent
skin-barrier defect predisposes the skin to carcinogenesis. We
speculate that the plurality of the cellular effectors (i.e., fibroplasia,Cancer Cell 16, 55–66, July 7, 2009 ª2009 Elsevier Inc. 63
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barrier collectively contribute to tumor promotion in this model.
We have previously identified several of these factors. Matrix
metallopeptidases (MMP8 and MMP9) are elevated in Notch1-
deficient skin at P9 as is osteopontin (Demehri et al., 2008). All
these stromal-derived factors are potential tumor promoters (Pa-
zolli et al., 2009; van Deventer et al., 2008). In addition, dermal
fibroblasts in Notch1-deficient skin are overproducing SDF-1
and KGF that directly stimulate keratinocyte proliferation; this
is reminiscent of carcinoma-associated fibroblasts known to
promote tumor development from a non-tumorigenic cell popu-
lation (Bhowmick et al., 2004; Orimo and Weinberg, 2006).
Furthermore, accumulation of immune cells and development
of a subacute inflammation in Notch1-deficient skin, triggered
by cytokines/chemokines released from barrier-defective
epidermis (Demehri et al., 2008; Segre, 2006; Yoo et al., 2005),
have been shown to promote skin carcinogenesis (Johansson
et al., 2008). From this large pool of tumor-promoting stromal
cells/factors present in Notch1-deficient skin, we examined the
contribution of a single component (Mast cells), which has
been previously deemed critical in skin carcinogenesis (Cous-
sens et al., 1999; de Visser et al., 2005; Tlsty and Coussens,
2006), and asked if the components listed above act redundantly
or are all required individually. Our results are consistent with the
possibility that removal of any single stromal component would
not significantly alter the tumor-promoting effect of the wound
microenvironment. Therefore, we propose that the tumor promo-
tion in Notch1-deficient skin results from the additive contribu-
tions of fibroplasia, angiogenesis, and inflammation. The cumu-
lative effect of these factors on skin carcinogenesis in the
presence of severe barrier defects that cause a full-blown inflam-
matory disease (i.e., AD) remains a topic for future investigation.
Taken together, Notch1- and Notch2/3-deficient mice demon-
strate that stroma of a chronic skin wound is analogous to tumor
stroma and can be used to determine the specific contribution of
each stromal component to tumor development, a worthy ques-
tion that falls outside the scope of the current study.
In conclusion, the persistent barrier defects in Notch-deficient
skin, which resemble chronic wounds, recruit several mesen-
chymal components necessary to repair the barrier. In turn, the
vascularized and growth factor-rich stroma provides initiated
cells with nutrients and proliferative signals that can directly
promote tumor formation. Thus, Notch1 is not a classical tumor
suppressor that solely exerts its effects cell autonomously (e.g.,
promotes cell death or cell-cycle arrest). Notch-deficient mice
provide instead a suitable system in which to dissect out the
molecular mediators and the cellular interactions that are
responsible for oncogenic effect of chronic wound/tumor
stroma. Based on such an analysis, new therapeutic targets
can be identified in the tumor microenvironment that will be
useful in developing molecular therapies for cancers of skin
and perhaps other organs (Albini and Sporn, 2007).
EXPERIMENTAL PROCEDURES
Generation of Mutant Mice
All the mice were maintained in the Washington University animal facility
according to animal care regulations, and the Animal Studies Committee
of Washington University approved the experimental protocols.64 Cancer Cell 16, 55–66, July 7, 2009 ª2009 Elsevier Inc.The mutant strains of mice analyzed in the current study were generated
following the protocol described previously (Pan et al., 2004). All the animals
were maintained in mixed C57BL/6 and CD1 genetic backgrounds, which
were overall resistant to DMBA/TPA skin carcinogenesis. In some experi-
ments, remnant contributions from 129sv and FVB strains might have also
been present. In all cancer experiments, age-matched littermates were
compared and nested ANOVA was used to confirm that strain-based differ-
ences did not confound our analysis. In studies related to spontaneous carci-
nogenesis and longevity, mice were monitored regularly for onset, number,
and size of tumors and any sign of failure to thrive. Moribund mice are eutha-
nized and skin, tumors, and lymph nodes are harvested.
Chemical Skin Carcinogenesis Studies
For DMBA/TPA experiments in Msx2-Cre background, mutant mice and their
age-matched littermate controls were treated with standard protocols for skin
chemical carcinogenesis models as previously described (Nicolas et al., 2003).
Further details are presented in Supplemental Experimental Procedures.
Histology, Immunohistochemistry, and Flow Cytometry (FC)
For hematoxylin and eosin (H&E), toluidine blue, and immunostaining using
paraffin-embedded tissue sections, skin, tumor, and lymph node samples
from various mutant and wild-type animals were fixed in 4% paraformalde-
hyde in PBS, dehydrated with ethanol, and embedded in paraffin, which
were then sectioned at 5 mm. X-gal staining was done on the skin prior to fixa-
tion with 4% paraformaldehyde as previously described (Pan et al., 2004).
Antibodies used for immunohistochemistry are listed in the Supplemental
Experimental Procedures. For FC analysis, single-cell suspensions from
dermis, peripheral blood, and spleen were prepared as described previously
(Demehri et al., 2008). Dermal cells were isolated using a Brinkmann Tissue
Chopper and crude collagenase (Sigma) digestion for 90 min at 37C.
Single-cell suspensions were stained with antibodies listed in the supple-
mental information.
ELISA and Immunoblotting
Serum TSLP concentrations were measured using Quantikine mouse TSLP kit
(R&D Systems). Serum IgE was measured using Mouse IgE ELISA kit (Immu-
nology Consultants Laboratory Inc.). Epidermal samples were collected in
NP40 lysis buffer as previously shown (Lee et al., 2007; Nicolas et al., 2003).
Protein lysates were run on SDS-PAGE gels after adjusting for protein concen-
tration and analyzed using anti-active b-catenin antibody (Upstate Biotech-
nology) and total b-catenin (BD Biosciences).
Dye Penetration Assay
To detect defects in skin-barrier function (Hardman et al., 1998), intact E18.5
embryos were stained in X-gal (pH 4.5) for 12 hr at 37C. After X-gal staining,
the embryos were washed in PBS three times and photographed with a digital
camera.
PCR and Quantitative RT-PCR
Conventional PCR for Notch1 allele was performed on genomic DNA isolated
from skin tumors of DMBA/TPA-treated Msx2-N1CKO mice using KlenTaq10
(DNA Polymerase Technology) supplemented with 1.3 M final concentration of
betaine (amplification cycles = 32). Quantitative RT-PCR (qRT-PCR) was per-
formed on mRNA isolated from skin and epidermis of Msx2-N1CKO, Msx2-
N2N3CKO mice and their wild-type littermates as previously described (Lee
et al., 2007). The primers used are listed in Table S7.
Statistical Analysis
The studies in this report were conducted in outbred cohorts of mice resem-
bling human population. To minimize the effect of susceptibility differences
due to genetic background on tumor phenotype observed in each study,
age-matched littermates were used as controls. We used power analysis to
estimate the number of mice needed in each group to reach statistical signif-
icance (Table S8). In addition, to confirm that the differential tumor parameters
we measured were conferred by status of gene (e.g., Notch1) deletion and not
by heritable factors (strain) or gender, we used nested ANOVA (SPSS; Tables
S2–S6). Further details are presented in Supplemental Experimental Proce-
dures. ‘‘Time to tumor onset’’ and ‘‘survival’’ data were analyzed using log
Cancer Cell
Notch1 Loss Creates a Tumor-Promoting Environmentrank test to determine significant differences. Tumor counts and other quanti-
tative measurements were assessed using Student’s t test. These quantitative
data are presented as mean ± SD for each measured parameter.
SUPPLEMENTAL DATA
Supplemental Data contain Supplemental Experimental Procedures, 15 fig-
ures, and eight tables and can be found with this article online at http://
www.cell.com/cancer-cell/supplemental/S1535-6108(09)00178-0.
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